CYP21A2 rs121908739: Understanding 21-Hydroxylase Deficiency
The rs121908739 variant is a well-characterized genetic change located within the CYP21A2 gene. It is associated with 21-hydroxylase deficiency, a condition that can lead to congenital adrenal hyperplasia and, in some cases, ambiguous genitalia in females.
What each genotype means
Typical enzyme function
This genotype represents the typical sequence for the CYP21A2 gene. Individuals with this profile are expected to have normal 21-hydroxylase enzyme activity, which is necessary for proper hormone production in the adrenal glands.
This is the most common genotype found in the general population across all ancestries.
Carrier of enzyme deficiency
This genotype indicates you carry one copy of a variant associated with 21-hydroxylase deficiency. Carriers typically do not exhibit symptoms of the condition, as the other copy of the gene usually provides sufficient enzyme function, but you may wish to discuss reproductive carrier screening with a genetic counselor.
This genotype is carried by roughly 1 in 50 to 1 in 100 people, depending on ancestral background.
Reduced or absent enzyme activity
This genotype is associated with 21-hydroxylase deficiency, a condition that can affect hormone production and lead to clinical manifestations such as congenital adrenal hyperplasia. Because this is a medical condition, individuals with this result should consult with an endocrinologist or clinical geneticist to discuss health management and appropriate care.
This genotype is rare in the general population, occurring significantly less frequently than the carrier state.
What is the rs121908739 Variant?
The rs121908739 variant is a specific genetic alteration found within the CYP21A2 gene, which is located on chromosome 6. This gene is situated in a complex region of the genome that includes a nonfunctional pseudogene, CYP21A1P. Because the functional gene and the pseudogene share high sequence similarity, genetic material can sometimes be exchanged between them, leading to mutations. rs121908739 represents a significant change that disrupts the normal function of the gene. In the context of genetic testing, this variant is often identified as a pathogenic marker for conditions related to adrenal hormone synthesis. Understanding its location is crucial for clinicians and researchers, as it helps in identifying the specific molecular cause of hormonal imbalances in affected individuals.
The Role of the CYP21A2 Gene
The CYP21A2 gene provides the essential instructions for producing an enzyme called 21-hydroxylase. This enzyme is primarily active in the adrenal glands, which are small organs located on top of the kidneys. 21-hydroxylase plays a critical role in the biosynthetic pathway that produces two vital hormones: cortisol and aldosterone. Cortisol is necessary for managing stress and maintaining blood sugar levels, while aldosterone helps regulate blood pressure and electrolyte balance. When the CYP21A2 gene is mutated, the resulting 21-hydroxylase enzyme may be partially or completely nonfunctional. This deficiency prevents the body from efficiently converting precursor molecules into cortisol and aldosterone. Consequently, these precursors are diverted into an alternative pathway, leading to an overproduction of androgens, which are male sex hormones. This hormonal shift is the underlying cause of the clinical features observed in 21-hydroxylase deficiency.
Research and Clinical Associations
Research has firmly established that mutations in CYP21A2, including rs121908739, are the primary cause of 21-hydroxylase deficiency. The clinical impact of these variants is categorized into different forms based on the remaining enzyme activity. The most severe form, known as the salt-wasting type, occurs when the enzyme is completely nonfunctional, leading to life-threatening imbalances in salt and water. The simple virilizing type allows for low levels of enzyme activity, while the non-classic form results in reduced but more significant enzyme production. The evidence linking these variants to congenital adrenal hyperplasia is strong and widely accepted in the medical community. Because the severity of the condition depends on the specific combination of inherited variants, genetic testing is often used to help characterize the potential clinical phenotype, though it should always be interpreted by a qualified healthcare professional.
Population Frequency and Prevalence
The prevalence of 21-hydroxylase deficiency varies significantly across different ethnic and geographic populations. The classic form of the disorder is estimated to occur in approximately 1 in 15,000 newborns, while the non-classic form is more common, affecting roughly 1 in 1,000 individuals. Carrier frequency for pathogenic CYP21A2 mutations is generally estimated to be between 1 in 10 and 1 in 25 in many populations. Because this is a recessive condition, an individual must typically inherit two copies of a pathogenic variant to manifest the classic symptoms. The carrier frequency of 0.01–0.02 noted for this specific variant highlights that while it is not common in the general population, it is a significant contributor to the overall burden of the disorder in specific groups.
Managing Genetic Information
If you or a family member have been identified as a carrier of a CYP21A2 variant, it is important to understand that this information is for educational purposes and does not constitute a medical diagnosis. Genetic testing results should always be discussed with a genetic counselor or a medical specialist, such as an endocrinologist. They can provide context regarding your specific results, explain the implications for family planning, and discuss whether any clinical monitoring is necessary. You cannot use this information to self-diagnose or alter any medical treatments. If you are currently taking medication related to adrenal health, do not change your dosage or discontinue use without consulting your clinician or pharmacist. Genetic information is a tool for informed health management, and professional guidance is essential for navigating the clinical implications of these findings.
How common is this variant?
The carrier frequency for pathogenic CYP21A2 mutations is estimated to be between 1:25 and 1:10, though this varies by ancestry.
Frequently asked questions
What is 21-hydroxylase deficiency?
21-hydroxylase deficiency is an inherited disorder where the adrenal glands cannot produce enough cortisol and aldosterone. This leads to an excess of male sex hormones, which can cause physical changes and health complications.
Is rs121908739 dangerous?
The variant is associated with a known medical condition. Whether it poses a health risk depends on your overall genetic profile and whether you have inherited the variant from one or both parents.
Do I need to see a doctor if I have this variant?
If you have received a report indicating you carry this variant, it is recommended to discuss the findings with a genetic counselor or an endocrinologist. They can help you understand what the result means for your health and family planning.
Can I treat this with supplements?
No, 21-hydroxylase deficiency is a complex hormonal condition that requires medical management by a specialist. Never attempt to treat or manage this condition with supplements or self-prescribed medications.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908739?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP21A2
Pathogenic variant (p.Val282Leu) in CYP21A2 associated with non-classic congenital adrenal hyperplasia.
Pathogenic variant associated with non-classic congenital adrenal hyperplasia presenting with hyperandrogenism, oligomenorrhea, and subfertility.
Pathogenic missense variant in CYP21A2 associated with 21-hydroxylase deficiency, a cause of congenital adrenal hyperplasia.
Pathogenic variant in CYP21A2 associated with 21-hydroxylase deficiency, used in reproductive carrier screening.
Well-characterized pathogenic missense variant (p.Pro30Leu) causing non-classic congenital adrenal hyperplasia and female hyperandrogenic subfertility.
This variant in the CYP21A2 gene is involved in steroid hormone metabolism and is noted in clinical databases.